The molecular mechanisms underlying major depressive disorder (MDD) are largely unknown. Limited success of previous genetics studies may be attributable to heterogeneity of MDD, aggregating biologically different subtypes. We examined the polygenic features of MDD and two common clinical subtypes (typical and atypical) defined by symptom profiles in a large sample of adults with established diagnoses. Data were from 1530 patients of the Netherlands Study of Depression and Anxiety (NESDA) and 1700 controls mainly from the Netherlands Twin Register (NTR). Diagnoses of MDD and its subtypes were based on DSM-IV symptoms. Genetic overlap of MDD and subtypes with psychiatric (MDD, bipolar disorder, schizophrenia) and metabolic (body mass index (BMI), C-reactive protein, triglycerides) traits was evaluated via genomic profile risk scores (GPRS) generated from meta-analysis results of large international consortia. Single nucleotide polymorphism (SNP)-heritability of MDD and subtypes was also estimated. MDD was associated with psychiatric GPRS, while no association was found for GPRS of metabolic traits. MDD subtypes had differential polygenic signatures: typical was strongly associated with schizophrenia GPRS (odds ratio (OR) = 1.54, P = 7.8e-9), while atypical was additionally associated with BMI (OR = 1.29, P = 2.7e-4) and triglycerides (OR = 1.21, P = 0.006) GPRS. Similar results were found when only the highly discriminatory symptoms of appetite/weight were used to define subtypes. SNP-heritability was 32% for MDD, 38% and 43% for subtypes with, respectively, decreased (typical) and increased (atypical) appetite/weight. In conclusion, MDD subtypes are characterized by partially distinct polygenic liabilities and may represent more homogeneous phenotypes. Disentangling MDD heterogeneity may help the psychiatric field moving forward in the search for molecular roots of depression.
INTRODUCTION
Major depressive disorder (MDD) is highly prevalent 1 and one of the main contributors to disability worldwide. 2 Though the heritability of MDD has been estimated to be 37%, 3 the search for specific genetic variants has not yet been successful: the largest genome-wide association study (GWAS) mega-analysis to date detected no significant associations with common polymorphisms. 4 Statistical hints suggest that depression liability is polygenic, with the majority of variance due to joint effects of multiple loci with small effects scattered across the genome. 5, 6 Failure to detect single effects is attributable to underpowered sample sizes and depression's clinical heterogeneity, that additionally compromises the power of association studies. [5] [6] [7] [8] [9] Patients with the same diagnosis of MDD (any five out of nine DSM-5 accessory symptoms 10 ) may endorse very different symptom profiles. From clinical observations, criteria to identify two severe subtypes-each present in~25-35% of patients-based on more homogenous symptom profiles have been proposed: typical/ melancholic and atypical, 11 reflected in the DSM-5 specifiers for melancholic and atypical depression. However, not all DSM criteria have been justified by research, and recent studies based on datadriven techniques highlighted the importance of vegetative symptoms (particularly appetite and weight) in distinguishing subtypes (decreased in typical, increased in atypical). [12] [13] [14] [15] [16] [17] Increasing evidence suggests that subtypes are associated with different pathophysiological correlates: environmental stress (for example, childhood trauma), smoking and hypothalamicpituitary-adrenal axis hyperactivity appear more specific for typical depression, whereas obesity, metabolic dysregulations (for example, abdominal adiposity, hypertriglyceridemia) and inflammation upregulations appear more specific for atypical depression. 11, 18, 19 In line with this observation, we recently showed 20 that the association between a variant in the FTO gene and MDD was completely driven by the atypical subtype. On the basis of these findings, we hypothesized that MDD subtypes may be characterized by a partially distinct genetic liability, with genetic profiles for stress-related and psychiatric traits more specifically linked with typical MDD, and those for obesity-related metabolic dysregulations with atypical MDD.
We tested our hypothesis in a sample of 3230 Dutch adults with established psychiatric diagnoses and GWAS data. We examined for MDD and its subtypes: (i) the genetic overlap with major psychiatric disorders (MDD, bipolar disorder, schizophrenia) and metabolic traits (body mass index (BMI), C-reactive protein (CRP) and triglycerides, capturing central metabolic dysregulations found to be strongly linked with atypical MDD 11, 18, 19 ) using genomic profile risk scores (GPRS); (ii) the proportion of variance in liability explained by the joint effect of all common single nucleotide polymorphisms (SNPs) using genomic-relationshipmatrix restricted maximum likelihood (GREML) methods. MDD subtypes were identified by using both data-driven techniques and a parsimonious sub-phenotyping strategy focusing on appetite and weight symptoms.
MATERIALS AND METHODS

Study population
The sample consisted of 3230 participants (median year of birth 1967, range 1926-1994; 64.7% females) of North-European ancestry from the Netherlands Study of Depression and Anxiety (NESDA, n = 1846) and from the Netherlands Twin Register (NTR, n = 1384). Unrelated participants were selected applying a cutoff threshold of 0.025 (that is, no closer relationships than third or fourth cousin) to a relationship matrix measuring genetic similarity calculated using GCTAv.1.24.1. 21 Detailed descriptions of the rationale, design and methods for both studies are given elsewhere. 22, 23 Briefly, NESDA is an ongoing cohort study into the long-term course and consequences of depressive and anxiety disorders. In 2004-2007, 2981 participants aged 18-65 years were recruited from the community (19%), general practice (54%) and secondary mental health care (27%) and were followed-up during three biannual assessments. The NTR study has been collecting data on Dutch twin families since 1991 and comprises longitudinal data on nearly 40 000 adult participants. The research protocols from both studies were approved by the ethical committee of participating universities, and all participants provided written informed consent.
MDD ascertainment
The sample included 1530 patients with a lifetime diagnosis of MDD and 1700 screened healthy controls. All cases were drawn from NESDA. Presence of DSM-IV lifetime diagnosis of MDD was assessed using the Composite Interview Diagnostic Instrument (CIDI, version 2.1) 24 administered by specially trained research staff at baseline or one of the biannual follow-up assessments. From NESDA, 316 healthy controls were also selected, including participants without any lifetime psychiatric disorder. The majority of controls (n = 1384) were drawn from NTR participants who had no reports of MDD, no known firstdegree relatives with MDD and a low factor score based on a multivariate analyses of depressive complaints, anxiety, neuroticism and somatic anxiety. 25 Case-control selection criteria in the present study are the same as previously applied to include NESDA and NTR participants in the Genetic Association Information Network (GAIN) MDD dataset, 25 which was used in previous studies [26] [27] [28] [29] including the largest MDD GWAS available to date by the Psychiatric Genomics Consortium. 4 Of note, 1452 cases and 99 controls from the current study were previously included in the larger (1943 cases,1807 controls) GAIN-MDD dataset (dbGaP Study Accession: phs000020.v2.p1). In GAIN, cases and controls were genotyped on a different platform (Perlegen-Affymetrix 5.0, Mountain View, CA, USA) as compared with the current study (Affymetrix 6.0, Santa Clara, CA, USA).
Determination of MDD subtypes
Among cases, 1477 subjects had MDD symptom-level data ascertained by the CIDI interview for the most severe episode in lifetime. Data on neurovegetative symptoms (appetite, weight, sleep and psychomotor disturbances) were disaggregated to code separately for increase, decrease and both increase/decrease. Subtypes of MDD were derived using two strategies. First, lifetime depression symptoms were used as input variables in a latent class analysis (LCA; Supplementary Methods) clustering persons on the basis of their endorsed symptom profiles. A 3-class model was found to fit the data best, similarly to previous results obtained applying LCA to NESDA patients with current MDD (extensive descriptions of subtypes and their correlates have been previously published 15, 16, 18 ). Two classes were characterized by high severity and were labeled 'severe typical' and 'severe atypical' based on symptom profiles. Consistent with other latent modeling studies [12] [13] [14] [15] [16] 18 the most discriminating symptoms were appetite and weight, decreased in typical and increased in atypical. Of note, LCA subtypes do not necessarily overlap with DSM classification of melancholic and atypical. The third class was labeled 'moderate' and was characterized by lower severity. For the analyses based on LCA subtypes, we initially included 1176 patients (~80% of those available) whose class could be assigned with confidence (average posterior probability40.7, indicating adequate separation and classification precision 30 ). Proportions of the subtypes were 19.4% for severe typical, 21.3% for severe atypical and 59.3% for moderate.
In large collaborative studies, symptom-level data necessary to apply more sophisticated data-driven techniques may not be available in all involved cohorts. For this reason, we additionally tested an alternative parsimonious sub-phenotyping strategy using only information on the direction of change in appetite and weight, as these were the symptoms with the highest discriminative power between subtypes (Supplementary Methods). Among the 1477 patients with available data, two subtypes, namely 'decreased appetite/weight' (39.7% of sample) and 'increased appetite/weight' (26.2%), were defined by the presence of, respectively, decrease or increase in at least one of the two symptoms. The proportion of MDD cases with lifetime anxiety disorder did not differ across typical and atypical subtypes (respectively, 84.7% and 81.3%; P = 0.33), nor across decreased and increased appetite/weight subtypes (respectively, 76.3% and 80.3%; P = 0.15). Supplementary eFigure 1 summarizes the number of subjects included/excluded for both sub-phenotyping strategies.
Genotyping, quality control and genetic relationship matrix Methods for biological sample collection and DNA extraction have been described previously. 25 Autosomal SNPs were genotyped on the Affymetrix 6.0 Human Genome-Wide SNP Array in three separate batches. Main quality control (QC) steps have been previously described. 31, 32 Primary analyses included 497 347 SNPs. Additional stringent QC was performed to build a genetic-relationship-matrix to reduce the possibility that estimates from genetic-relationship-matrix-based analyses could be inflated by artifacts. The remaining 435 579 SNPs were used to build the geneticrelationship-matrix using GCTAv.1.24.1.
21 All QC steps are described in Supplementary Methods.
Genomic profile risk scores (GPRS)
GPRS for psychiatric and metabolic traits were generated based on discovery GWAS meta-analysis results from large international consortia (see Supplementary Methods for detailed description). Results from the Psychiatric Genomics Consortium (PGC) were used to derive GPRS for MDD 4 (~8 K cases,~8 K controls), bipolar disorder 33 (BIP;~7 K cases, 9 K controls) and schizophrenia 34 (SCZ2;~36 K cases,~113 K controls). Discovery GWAS meta-analyses for metabolic traits were from GIANT Consortium 35 for BMI (~120 K samples), Dehghan et al. 36 for CRP (~70 K samples) and Teslovich et al. 37 for triglycerides (TR;~100 K). Because NESDA and NTR samples contributed to MDD and BMI discovery GWAS, meta-analyses for these traits were performed with the Dutch GWAS cohort excluded to remove any chance of overlap between discovery and target samples. For all traits, eight sets of independent SNPs were selected based on significance thresholds (Pt o0.0001, o 0.001, o 0.005, o0.01, o0.05, o0.1, o0.5, o 1) of the discovery samples associations. GPRS were calculated as the number of scores alleles weighted by effect sizes from the discovery statistics using PLINKv1.07 38 and were standardized to aid interpretation of the results. Number of SNPs included in the GPRS according to Pt are reported in Table 1 .
Statistical analyses
Differences in year of birth and gender across MDD cases and controls were tested using Wilcoxon-Mann-Whitney and chi-square statistics. Cross-correlations between GPRS were evaluated with Pearson's coefficient. The association of GPRS with MDD (subtypes) was estimated by (multivariate) logistic regressions with controls as the reference category. The proportion of variance explained by GPRS on the liability scale for MDD (subtypes) was estimated using the R 2 coefficient proposed by Lee et al., 39 which is directly comparable with heritability and robust against ascertainment bias. Linear transformation on the liability scale was based on prevalence (K) of 0.18 for MDD (Dutch lifetime prevalence 40 ); Ks for subtypes were empirically derived based on subtypes proportions among cases. To examine the overlap between subtypes obtained with different sub-phenotyping strategies, the performance of appetite/ weight subtypes to predict the corresponding LCA subtypes (decreased appetite/weight → typical and increased appetite/weight → atypical) was evaluated using receiver operating characteristic analyses. All analyses were performed with SAS (v. 9.2, SAS Institute, Cary, NC, USA) and R (v. 3.0.1, R Project for Statistical Computing). Finally, the total variance in liability to MDD (subtypes) explained by the joint effect of all SNPs (SNPheritability, h 2 SNP ) was estimated using GREML analyses 41 implemented in GCTAv.1.24.1 (ref. 21) . SNP-heritability is estimated in a linear mixed model in which the measure of genetic similarity (based on the genetic-relationship-matrix) is included as a random effect to predict the phenotype. All analyses were corrected for year of birth, gender and three ancestryinformative principal components 32 to take possible population stratification into account. Significance level was set at Po0.05, two-tailed. Psychiatric traits GPRS analyses MDD case-control status (Figure 1a ; full results available in Supplementary eTable 1) was significantly predicted by the GPRS of psychiatric traits, especially at liberal Pts. Psychiatric GPRS including all independent SNPs (Pto1) were significantly, although not strongly, correlated (MDD-BIP r = 0.22; MDD-SCZ2 r = 0.16; BIP-SCZ2 r = 0.27; all Po0.0001). When including all three scores in the same model for Pt bins o0.05, o0.01, o0.5 and o1, only GPRS-MDD and GPRS-SCZ2 remained independently associated with MDD. Analyses were repeated including dummy covariates indexing the different genotyping batches and results were essentially unchanged (data not shown). The variance explained on the liability scale for MDD is shown in Figure 2a . GPRS-SCZ2 explained the higher proportion of variance, up to 1.6%, while GPRS-MDD and GPRS-BIP explained up to, respectively, 0.6% and 0.3%. The figure includes also GPRS-SCZ1 derived from the first PGC-GWAS on schizophrenia 42 (~9 K cases,~12 K controls) to highlight the importance of discovery sample size in GPRS predictive performance: 43 GPRS-SCZ1 predicted at best up to 0.5% of the variance on MDD liability. To further confirm these findings, we used the equations based on genetic quantitative theory developed by Dudbridge 43 to estimate the expected predictive accuracy of GPRS Pto0.5 (the best performing threshold) as a function of parameters such as discovery sample size (Supplementary Methods). The theoretical estimates of explained variance were highly convergent (GPRS-MDD 0.5%, GPRS-BIP 0.3%, GPRS-SCZ2 1.2%, GPRS-SCZ1 0.3%) with the empirical values of explained variance obtained in the present study. More interestingly, a model assuming GPRS-MDD based on a discovery sample of the same size of SCZ2 indicated that an even larger amount of variance explained in MDD liability could be expected (3%). Figure 1 graphically depicts the associations between GPRS with LCA-based typical and atypical subtype estimated by multinomial logistic regressions (associations with MDD are also depicted as benchmark for comparison; full results including moderate subtype are available in Supplementary eTables 2, 3) . In general, GPRS for psychiatric traits were also associated with both severe subtypes, but the associations were stronger with typical, especially for GPRS-SCZ2 (Pto 0.5:odds ratio (OR) = 1.54, 95% confidence interval (CI) = 1.33-1.78, P = 7.8e-9). GPRS-SCZ2 explained up to 1.3% of the variance for atypical, similar to MDD, and up to 2.4% for typical MDD (Figures 2c and e) .
RESULTS
Descriptives
Metabolic traits GPRS analyses
No association was found for GPRS of metabolic traits with MDD ( Figure 1b; Supplementary eTable 1) . Among the metabolic traits, GPRS-BMI (Pt o0.0001:OR = 1.29, 95%CI = 1.12-1.47, P = 2.7e-4) and GPRS-TG (Pt o0.005:OR = 1.21, 95%CI = 1.06-1.38, P = 0.006) were associated with atypical MDD, particularly at stringent Pts. Cross-correlation between GPRS-BMI and GPRS-TG was low even at Pto 1 including all independent SNPs (r = 0.04; P = 0.02). When including both GPRS in the same model they remained independently associated with atypical in Pt bins o0.0001, o0.001, o 0.005, o 0.01 and 0.05. Figure 2f shows that GPRS-BMI explained up to 1.2% and GPRS-TG up to 0.5% of the variance for atypical MDD. GPRS for metabolic traits were not associated with typical MDD (Figure 1b, Supplementary eTable 3) .
Association analyses between LCA-based subtypes with all GPRS were repeated after lowering the cutoff for classification precision (average posterior probability40.6, including up tõ 90% of the available subjects with symptom-level data) and results were very similar (data not shown).
Alternative sub-phenotyping Subtypes defined by increase/decrease in appetite/weight were tested next. Increased appetite/weight almost perfectly predicted LCA-atypical (area under the curve:0.99; 95%CI = 0.98-1.00; sensitivity 98.4%; specificity 99.5%), while the prediction of LCAtypical by decreased appetite/weight subtype was less accurate (area under the curve:0.81; 95%CI = 0.78-0.83; sensitivity 87.8%; specificity 72.8%), suggesting that other symptoms beyond appetite/weight may be relevant to reliably identify this subtype. The decreased appetite/weight subtype captured indeed a large proportion of participants classified in LCA moderate class (Supplementary Methods). Multinomial logistic regression analyses testing the associations between GPRS and appetite/weight subtypes resulted in profiles (Supplementary eFigure 2) similar to LCA-subtypes. In a sensitivity analysis addressing the impact of the symptoms increased weight when testing the association with GPRS-BMI, we identified the atypical-like cases (N = 364) using only the symptom increased appetite. The strength of the association (OR = 1.19, 95%CI = 1.06-1.34, P = 0.004) with GPRS-BMI Pt o 0.0001 was similar to that found when combining the two symptoms in the increased appetite/weight sub-phenotype (OR = 1.20, 95%CI = 1.06-1.33,P = 0.003; Supplementary eFigure 2).
GREML analyses
Results from GREML analyses showed that common SNPs significantly captured a substantial part of the heritability of MDD (estimate = 0.31; s.e. = 0.13; P = 0.006). We estimated also h 2 SNP for the subtypes defined by appetite/weight symptoms because they allowed us to include a higher number of cases (587 decreased, 385 increased) as compared with LCA subtypes (228 typical, 251 atypical). With the available sample size, for both subtypes, 80% power to detect a significant (40) h 2 SNP could be reached only assuming heritability estimates higher than those for MDD (Supplementary eFigure 3) . Estimates of h 2 SNP were significant for both decreased (K = 0.072; estimate = 0.38; s.e. = 0.17; P = 0.01) and increased (K = 0.047; estimate = 0.43; s.e. = 0.20; P = 0.01) appetite/ weight, and higher than those for MDD, although with large standard errors due to restricted sample sizes.
DISCUSSION
In a large sample of depressed adults and controls with GWAS data, we examined the polygenic features of MDD and two Abbreviations: BIP, bipolar disorder; BMI, body mass index; CRP, C-reactive protein; GPRS, genomic profile risk score; MDD, major depressive disorder; SCZ, schizophrenia; SNP, single nucleotide polymorphism; TG, triglycerides.
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common subtypes, typical and atypical, defined on the basis of symptom profiles. We confirmed that MDD disease liability reflects the combined small effects of a large number of genetic variants across the genome. 5, 6 MDD case-control status was significantly predicted by GPRS-MDD based on the largest dataset to date, 4 especially by scores including SNPs associated with MDD at liberal significance thresholds. This pattern indicates that the explanatory power of the scores is increased by the addition of many variants of small effect scattered across the genome. The score including all independent SNPs explained 0.6% of the variance in MDD liability. Consistently with previous cross-disorders analyses by PGC, 28, 29 we also confirmed that MDD shares genetic risk with major psychiatric disorders such as bipolar disorder and schizophrenia. Figure 1 . (a) GPRS for psychiatric traits; (b) GPRS for metabolic traits. Associations of GPRS for psychiatric and metabolic traits with MDD and subtypes (severe typical and severe atypical). Results (odds ratios and 95% confidence intervals) from binary (MDD: 1530 cases) and multinomial (subtypes: 228 severe typical, 251 severe atypical) logistic regressions (reference: 1700 controls) adjusted for year of birth, gender and three ancestry-informative principal components.
GPRS-BIP
Among the GPRS for psychiatric disorders, schizophrenia scores explained the highest proportions of variance in MDD liability (1.6%). This higher explanatory power is attributable to the larger training dataset, 43 leading to smaller sampling variance on the individual SNP effects. For GPRS based on the latest schizophrenia PGC-GWAS, 34 the discovery sample size was~150 K samples, whereas this was~16 K for GPRS based on MDD 4 and bipolar disorder. 33 In a seminal paper, Dudbrige 43 elegantly showed that the accuracy of GPRS predictions depends on the size of the training samples. Because PGC cross-disorder analyses showed 28 that MDD could be predicted by GPRS for the other psychiatric disorders, we could expect that-owing to a training sample that was almost 10 times larger-the schizophrenia GPRS may explain a portion of MDD variance even larger than GPRS for the same trait. Using Dudbrige's equations 43 estimating the predictive accuracy of GPRS as a function of parameters such as discovery sample size, we confirmed the empirical values of explained variance obtained in the current study. More interestingly, results indicated that the availability of a discovery GWAS for MDD of the same size as that for schizophrenia, may lead to an even larger amount of variance explained in MDD liability by MDD GPRS.
These results confirmed that the predictive accuracy of GPRS should be always interpreted in light of the genetic characteristics of the specific trait and the size of the discovery sample; any attempt to frame findings from different GPRS in terms of simple direct comparisons between each other should be avoided.
The evidence of shared genetic risk factors between different psychiatric disorders has been previously interpreted as a first step in moving beyond descriptive syndromes toward a biologyinformed nosology. 28 A project pursuing this aim is represented by the National Institute of Mental Health's Research Domain Criteria (RDoC), which support research examining fundamental biobehavioral dimensions that cut across current heterogeneous disorder categories. 44 The present study used a similar approach and results are the first to show partially different polygenic signatures across MDD subtypes. While typical had a stronger genetic overlap with psychiatric traits, particularly with schizophrenia (2.4% explained variance), atypical MDD showed an additional contribution of genetic signals from the metabolic traits of BMI (1.2% explained variance) and triglycerides (0.5% explained variance). These findings show intriguing consistencies with previous clinical and research observations. The overlap between schizophrenia genetic risk and typical MDD is consistent with the common presence of psychotic symptoms in patients with melancholic depression. 45 Furthermore, previous findings from the NESDA cohort showed that patients categorized as severe typical were more likely to be smokers; 15, 16, 18 smoking is highly comorbid with psychiatric disorders, especially with schizophrenia, although the underlying biology is not well understood. 46 For the atypical subtype, converging epidemiological evidence suggests a correlation with obesity and immuno-metabolic alterations. 11, 18, 19 In the current study, atypical was associated with GPRS for BMI and triglycerides, particularly when based on SNPs strongly associated with traits at stringent significance threshold, suggesting the presence of loci of moderate effect. This is consistent with our previous findings showing the strong association between the FTO rs9939609-A variant and atypical MDD. 20 When tested, the FTO-atypical association was also independent from BMI; similarly, in the current study, the association of the best performing GPRS (Pto 0.0001) for BMI and triglycerides with atypical was reduced in effect size after controlling for BMI, but was still evident. Nevertheless, we decided not to adjust these analyses for BMI: our results of a shared genetic basis sustain indeed the hypothesis that atypical depression and BMI-related metabolic dysregulations may represent epiphenomenon stemming from the same pathophysiological mechanism, and adjusting for BMI may therefore represent an overadjustment. Nevertheless, the association with GPRS-BMI was unchanged when using only the increased appetite symptom to define the atypical-like subtype. Finally, no genetic overlap was found between MDD or the atypical subtype with CRP. This is in line with a recent large mendelianrandomization study showing that genetically elevated CRP is not associated with increased risk of depression. 47 Intriguingly, the differential polygenic signatures were found when deriving subtypes by LCA applied to all endorsed symptoms or by simply coding the direction of change (increase/decrease) in the highly discriminatory [12] [13] [14] [15] [16] 18 symptoms of appetite and weight. It should be highlighted that whereas increased appetite/ weight almost perfectly predicted LCA-atypical, the decreased appetite/weight → LCA-typical prediction was less accurate, suggesting that other symptoms beyond appetite/weight may be relevant to reliably identify this subtype. This should be carefully evaluated in specifically dedicated diagnostic-accuracy studies. Nevertheless, the possibility of using parsimonious and effective sub-phenotyping strategies may be relevant for large collaborative studies for which symptom-level data necessary to apply more sophisticated data-driven techniques may not be available in all involved cohorts. Moreover, symptom endorsement profiles may be highly variable across cohorts, reflecting differences such as settings (for example, clinical, population-based), ascertainment (for example, psychiatric interviews, medical records) or diagnosis timeframe (for example, lifetime, current). When applying typical/ atypical sub-phenotyping strategies, an important aspect to consider may be the possible impact of antidepressant medications, some of which may affect weight change and other metabolic disturbances. 48 For the current study, previous results from NESDA point toward a reduced likelihood of antidepressant medication impact. The antidepressant medication classes more commonly used were not cross-sectionally associated with metabolic dysregulations 49 nor with 2-year trajectories of weight change. 50 In another study 18 focusing on a subset of patients with current chronic MDD, antidepressant medications used were similar across typical and atypical subtypes; moreover, the differential associations across subtypes of characteristics such as waist circumference, BMI, triglycerides and CRP was unchanged after adjustment for antidepressant use.
Results of the present study also showed that 31% of the variance in MDD liability was explained by the joint effect of all common SNPs. This perfectly replicates the h 2 SNP estimate (0.32) obtained by a previous study based on the GAIN MDD dataset, 26 including overlapping cases with the current study and different controls genotyped on a different platform. Estimates of h 2 SNP were higher for the subtypes: 38% for MDD with decreased and 43% for MDD with increased appetite/weight. This suggests that subtypes may be genetically more homogeneous. It is important to remark, however, that owing to the limited sample size, the standard errors around the estimates were large. Nevertheless, our results are in line with recent twin-based estimates 51 showing higher heritability for atypical depression defined according to DSM-III (0.51) as compared with MDD (0.43).
Major strengths of the current study include the availability of GWAS data in a large sample well-characterized in terms of psychiatric diagnoses, the use of different sub-phenotyping strategies to identify MDD subtypes and GPRS based on large international consortia. An important limitation is that the sample size was still largely underpowered to perform bivariate-GREML analyses to calculate the SNP correlation (average genome-wide relationship) 41 between the subtypes. In summary, our results suggest that MDD subtypes based on symptom profiles are characterized by partially distinct polygenic liabilities and may represent more homogeneous phenotypes. Similarly to other complex diseases, MDD may represent a diagnostic aggregation of biologically different subtypes. As shown by recent simulations studies, 7, 8 this heterogeneity could severely compromise the power of association studies. Moreover, the finding of partially distinct genetic signature across more homogenous subtypes suggest translational implication in the long term: it could be hypothesized that distinct subtypes may specifically respond to different treatments. Our results provide proof-of-principle evidence that should stimulate further studies scaling up the dissection of MDD heterogeneity in larger samples. As we demonstrated, the use of cost-effective sub-phenotyping strategies to identify subtypes, in particular atypical, may be a successful strategy to harmonize phenotypes across different cohorts. While we dissected MDD along symptom profiles, other clinical features (for example, age of onset, post-partum onset, sensitivity to environmental stressors) may be also tested in future studies. Disentangling MDD heterogeneity (provided a constant parallel effort in increasing samples size of genetic studies) may help the psychiatric field moving forward in the search for molecular roots of depression.
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